These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1320587)

  • 21. 6-(Methoxymethylene)penicillanic acid: inactivator of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5839-46. PubMed ID: 6098300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.
    Hedberg M; Lindqvist L; Tunér K; Nord CE
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1100-4. PubMed ID: 1338315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S; Nicolas-Chanoine MH; Labia R
    FEMS Microbiol Lett; 1996 Sep; 143(1):29-33. PubMed ID: 8807798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    Diver JM; Thornber D; Wise R
    J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of beta-lactamase inhibitors on the activity of oxacillin against methicillin-resistant Staphylococcus aureus.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):81-4. PubMed ID: 7628197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.
    Sutherland R
    Infection; 1995; 23(4):191-200. PubMed ID: 8522374
    [No Abstract]   [Full Text] [Related]  

  • 32. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 34. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5833-9. PubMed ID: 6098299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
    Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
    FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and Functional Characterization of
    Cai J; Cheng Q; Shen Y; Gu D; Fang Y; Chan EW; Chen S
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Fonseca F; Sarmento AC; Henriques I; Samyn B; van Beeumen J; Domingues P; Domingues MR; Saavedra MJ; Correia A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4512-4. PubMed ID: 17875998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
    Prabhakaran K; Harris EB; Randhawa B; Hastings RC
    Microbios; 1995; 81(328):177-85. PubMed ID: 7752957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.